切换至 "中华医学电子期刊资源库"
高级检索
中华介入放射学电子杂志

中华介入放射学电子杂志 ›› 2022, Vol. 10 ›› Issue (02) : 209 -214. doi: 10.3877/cma.j.issn.2095-5782.2022.02.015

综述

原发性肝癌合并肝动脉-门静脉分流的介入治疗进展
焦盼1, 覃佳2, 陈旭颖1, 李超1, 张晓磷3,†()   
  1. 1. 443001　湖北宜昌，三峡大学附属第一临床医院介入放射科
    2. 443000　湖北宜昌，宜昌市中心人民医院介入放射科
    3. 443001　湖北宜昌，三峡大学附属第一临床医院介入放射科；443000　湖北宜昌，宜昌市中心人民医院介入放射科
  • 收稿日期:2021-07-28 出版日期:2022-05-25
  • 通信作者: 张晓磷

Advances in the interventional therapy of primary liver cancer combined with hepatic artery-portal vein shunts

Pan Jiao1, Jia Qin2, Xuying Chen1, Chao Li1, Xiaolin Zhang3,†()   

  1. 1. Interventional Radiology Department, First Affiliated Hospital of Three Gorges University, Hubei Yichang 443001
    2. Interventional Radiology Department, Yichang Central People's Hospital, Hubei Yichang 443000, China
    3. Interventional Radiology Department, First Affiliated Hospital of Three Gorges University, Hubei Yichang 443001; Interventional Radiology Department, Yichang Central People's Hospital, Hubei Yichang 443000, China
  • Received:2021-07-28 Published:2022-05-25
  • Corresponding author: Xiaolin Zhang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

焦盼, 覃佳, 陈旭颖, 李超, 张晓磷. 原发性肝癌合并肝动脉-门静脉分流的介入治疗进展[J]. 中华介入放射学电子杂志, 2022, 10(02): 209-214.

Pan Jiao, Jia Qin, Xuying Chen, Chao Li, Xiaolin Zhang. Advances in the interventional therapy of primary liver cancer combined with hepatic artery-portal vein shunts[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(02): 209-214.

肝癌合并动脉-门静脉分流在临床上并不鲜见，严重制约并影响介入治疗的实施与效果。随着介入器材、血管超选技术、栓塞材料的发展以及近些年针对肝癌免疫及靶向药物的开发，肝癌合并动脉门静脉分流患者的预后有了明显的改善。文章旨在总结肝细胞癌合并动脉-门静脉分流的介入治疗进展，并讨论目前介入治疗中存在的挑战。

关键词: 肝恶性肿瘤, 肝动脉化疗栓塞, 肝动静脉分流, 介入治疗

Hepatocellular carcinoma complicated with arterial-portal shunts is not uncommon in clinical practice, which seriously restricts and affects the implementation and outcome of interventional treatment. With the development of interventional devices, vascular superselection techniques, embolic materials and immune and targeted drugs for hepatocellular carcinoma in recent years, the prognosis of patients with hepatocellular carcinoma combined with arterial-portal shunts has improved significantly. The purpose of this article is to summarize the progress of interventional treatment for hepatocellular carcinoma with arterial-portal shunts and to discuss the current challenges in interventional treatment.

Key words: Hepatocellular carcinoma, Transarlerial chemoembolization, Arterio-portal shunt, Interventional therapy
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3): 209-249.
[2]
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[3]
Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35(9): 2155-2166.
[4]
孙磊, 施海彬, 刘圣,等. 肝细胞癌肝动脉门静脉分流形成的相关因素分析[J]. 介入放射学杂志, 2012, 21(3): 206-210.
[5]
Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment[J]. Curr Probl Diagn Radiol, 2015, 44(6): 479-486.
[6]
Jagannath S,Shalimar.Advances in management of hepatocellular carcinoma[J]. J Clin Exp Hepatol, 2016, 6(1): 68-70.
[7]
李万湖, 董帅, 胡旭东, 等. 多层螺旋CT血管造影对原发性肝癌动静脉瘘和肝外供血动脉评估价值[J]. 中华肿瘤防治杂志, 2017, 24(11): 755-758.
[8]
Heaston DK, Chuang VP, Wallace S, et al. Metastatic hepatic neoplasms: angiographic features of portal vein involvement[J].AJR Am J Roentgenol, 1981, 136(5): 897-900.
[9]
Fares N, Péron JM.Epidemiology, natural history, and risk factors of hepatocellular carcinoma[J]. Rev Prat, 2013, 63(2): 216-217, 220-222.
[10]
Chen X, Liu L, Pan X. Portal vein tumor thrombus in advanced hepatocellular carcinoma: a case report[J]. Oncol Lett, 2015, 9(6): 2495-2498.
[11]
林福煌, 吴宁, 李斯锐, 等. 原发性肝癌合并门静脉瘘TACE药代动力学影响因素的研究[J]. 实用癌症杂志, 2017, 32(10): 1674-1676, 1684.
[12]
Okuyama M, Fujiwara Y, Hayakawa T, et al. Esophagogastric varices due to arterioportal shunt in a serous cystadenoma of the pancreas in von Hippel-Lindau disease[J]. Dig Dis Sci, 2003, 48(10): 1948-1954.
[13]
中国医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]. 中华肝脏病杂志, 2019, 27(3): 172-181.
[14]
Shi HB, Yang ZQ, Liu S, et al. Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2013, 36(2): 412-421.
[15]
Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370.
[16]
Pua U. High-flow arterio-hepatic venous shunt in hepatocellular carcinoma: use of multi-electrode radiofrequency for shunt obliteration[J]. Cardiovasc Intervent Radiol, 2015, 38(5): 1330-1334.
[17]
Sacco R, Tapete G, Simonetti N, et al. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review[J]. J Hepatocell Carcinoma, 2017, 4: 105-110.
[18]
Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: a single-center randomized controlled trial[J]. Cancer Biol Ther, 2017, 18(6): 433-438.
[19]
Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data[J]. Hepatology, 2016, 64(1): 106-116.
[20]
Chan WS, Poon WL, Cho DH, et al. Transcatheter embolisation of intrahepatic arteriovenous shunts in patients with hepatocellular carcinoma[J]. Hong Kong Med J, 2010, 16(1): 48-55.
[21]
Xu HF, Yang RJ, Chen H, et al. Interventional therapy of hepatic artery-portal vein fistula with gelatin sponge and lipiodol[J].Zhonghua Yi Xue Za Zhi, 2011, 91(15): 1061-1063.
[22]
肖景坤, 吕维富, 周春泽, 等. 原发性肝癌伴动静脉瘘介入栓塞治疗62例回顾性分析[J]. 介入放射学杂志, 2014, 23(8): 683-687.
[23]
薛兴存, 武学伟. 阿霉素海藻酸钠微球联合碘化油肝动脉栓塞治疗肝癌合并动静脉分流效果观察[J]. 实用肝脏病杂志, 2017, 20(2): 246-247.
[24]
王福安, 眭未凡, 吕朋华, 等. 海藻酸钠微球联合肝动脉化疗栓塞治疗原发性肝癌的Meta分析[J]. 中华介入放射学电子杂志, 2016, 4(4): 192-196.
[25]
Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design[J]. J Hepatol, 2012, 56(6): 1330-1335.
[26]
郝明志, 林海澜, 余文昌, 等. 经肝动脉导管注射无水乙醇碘化油乳剂治疗肝癌动静脉瘘[J]. 中国介入影像与治疗学, 2006, 3(6): 432-435.
[27]
Li J, Kang X, Guo L, et al. Embolization of hepatic arterioportal shunt with ethanol-soaked gelatin sponge[J]. J Cancer Res Ther, 2019, 15(2): 336-340.
[28]
周卫忠, 刘圣, 杨正强, 等. 氰基丙烯酸酯胶栓塞原发性肝细胞癌合并重度肝动脉门静脉瘘12例疗效分析[J]. 介入放射学杂志, 2013, 22(8): 641-645.
[29]
宿贝贝, 董景辉, 王华明, 等. 肝脏原发性淋巴瘤1例报告[J].山东医药, 2015(40): 106-106.
[30]
Lyu N, Lin Y, Kong Y, et al. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J].Gut, 2018, 67(2): 395-396.
[31]
Akpek S,Ilgit ET,Cekirge S, et al.High-flow arterioportal fistula: treatment with detachable balloon occlusion[J].Abdom Imaging,2001,26(3):277-280.
[32]
Koc O, Cil BE, Peynircioglu B, et al. Complementary use of NBCA with the Amplatzer vascular plug for embolization of a high-flow traumatic hepatic arteriovenous fistula[J]. Cardiovasc Intervent Radiol, 2009, 32(5): 1105-1107.
[33]
Takao H, Shibata E, Ohtomo K. Double-balloon-assisted n-butyl-2-cyanoacrylate embolization of intrahepatic arterioportal shunt prior to chemoembolization of hepatocellular carcinoma[J].Cardiovasc Intervent Radiol, 2016, 39(10): 1479-1483.
[34]
Luo W, Zhang Y, He G, et al. Effects of radiofrequency ablation versus other ablating techniques on hepatocellular carcinomas: a systematic review and meta-analysis[J]. World J Surg Oncol, 2017, 15(1): 126.
[35]
Chinnaratha MA, Chuang MY, Fraser RJ, et al. Percutaneous thermal ablation for primary hepatocellular carcinoma: a systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2016, 31(2): 294-301.
[36]
Orlacchio A, Bolacchi F, Chegai F, et al. Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm[J]. Radiol Med, 2014, 119(5): 298-308.
[37]
Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma[J]. Hepatology, 2015, 61(5): 1579-1590.
[38]
Yang B, Zan RY, Wang SY, et al. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials[J]. World J Surg Oncol, 2015, 13: 96.
[39]
Sonomura T, Kawai N, Kishi K, et al. N-butyl cyanoacrylate embolization with blood flow control of an arterioportal shunt that developed after radiofrequency ablation of hepatocellular carcinoma[J]. Korean J Radiol, 2014, 15(2): 250-253.
[40]
Kallini JR, Gabr A, Salem R, et al. Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma[J].Adv Ther, 2016, 33(5): 699-714.
[41]
Gordon AC, Gabr A, Riaz A, et al. Radioembolization super survivors: extended survival in non-operative hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2018, 41(10): 1557-1565.
[42]
王舒婷, 陈海波, 施昌盛, 等. 经皮射频消融联合125I放射性粒子植入术治疗肝恶性肿瘤的疗效分析[J]. 介入放射学杂志, 2020, 29(6): 587-590.
[43]
Eriguchi T, Takeda A, Sanuki N, et al. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system[J]. Int J Radiat Oncol Biol Phys, 2013, 85(4): 1006-1011.
[44]
Korean Liver Cancer Association (KLCA), National Cancer Center (NCC).2018 Korean liver cancer association-national cancer center korea practice guidelines for the management of hepatocellular carcinoma[J]. Korean J Radiol, 2019, 20(7): 1042-1113.
[45]
Zhou J, Sun H, Wang Z, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)[J]. Liver Cancer, 2020, 9(6): 682-720.
[46]
Wong TC, Chiang CL, Lee AS, et al. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: a propensity score matched analysis[J]. Surg Oncol, 2019, 28: 228-235.
[47]
Rosenberg SA, Henke LE, Shaverdian N, et al. A multi-institutional experience of MR-guided liver stereotactic body radiation therapy[J]. Adv Radiat Oncol, 2019, 4(1): 142-149.
[48]
Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future[J]. Lancet Oncol, 2020, 21(2): e74-e82.
[49]
Llovet JM, Ricci S,Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
[50]
Thüring J, Zimmermann M, Bruners P, et al. Short-term oral sorafenib for therapy of intratumoral shunts of hepatocellular carcinoma to enable intraarterial treatment[J]. Cardiovasc Intervent Radiol, 2019, 42(10): 1494-1499.
[51]
曾云建, 毛颖民, 史自立, 等. 聚乙烯醇化疗栓塞联合阿帕替尼治疗晚期原发性肝癌合并动静脉分流的效果[J]. 介入放射学杂志, 2019, 28(10): 949-953.
[52]
Huang Y, Liu C, Zeng WC, et al. Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway[J]. Biosci Rep, 2020, 40(1): BSR20192727.
[53]
Yuan Q, Yao F, Zhou L, et al. Yu Ping Feng San exert anti-angiogenesis effects through the inhibition of TSLP-STAT3 signaling pathways in hepatocellular carcinoma[J]. Evid Based Complement Alternat Med, 2019, 2019: 1947156.
[54]
Su Q, Fan M, Wang J, et al. Sanguinarine inhibits epithelial-mesenchymal transition via targeting HIF-1α/TGF-β feed-forward loop in hepatocellular carcinoma[J]. Cell Death Dis, 2019, 10(12): 939.
[55]
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699.
[56]
Mazzaferro V, Bhoori S,Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience[J]. Liver Transpl, 2011, 17 Suppl 2: S44-57.
[57]
夏永祥, 张峰, 李相成, 等. 原发性肝癌10 966例外科治疗分析[J]. 中华外科杂志, 2021, 59(1): 6-17.
[1] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[2] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[3] 刘中百, 任勇军. 肝细胞癌的介入治疗现状及进展[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 111-115.
[4] 吴雅琴, 莫伟, 向华, 李琴, 李玉莲, 周碧芳. 肝癌患者介入术后股动脉穿刺处出血的研究进展[J]. 中华介入放射学电子杂志, 2023, 11(04): 352-356.
[5] 李世凯, 梁佳, 何艳艳, 于毅, 李天晓, 常金龙, 贺迎坤. 兔颈动脉粥样硬化性狭窄模型在介入治疗的应用进展[J]. 中华介入放射学电子杂志, 2023, 11(04): 357-362.
[6] 张德伟, 雷毅, 江哲宇, 王黎洲, 许国辉, 周石. 杂交手术治疗下肢深静脉血栓合并下肢急性动脉血栓一例[J]. 中华介入放射学电子杂志, 2023, 11(04): 380-384.
[7] 林加文, 印于, 杨俊, 朱晓黎, 王万胜. 肝动门静脉瘘合并腹水一例[J]. 中华介入放射学电子杂志, 2023, 11(03): 289-291.
[8] 吴雅琴, 莫伟, 向华, 李琴, 李兰. 肝癌患者介入治疗穿刺处出血影响因素的真实世界研究[J]. 中华介入放射学电子杂志, 2023, 11(02): 117-122.
[9] 董艳超, 牛洪涛. 封堵球囊微导管在超选择性动脉栓塞时应用价值与安全性综述[J]. 中华介入放射学电子杂志, 2023, 11(02): 164-171.
[10] 阴捷, 王驰, 刘玥, 李艳华. 儿童肝脏血管瘤的介入治疗方法及疗效的初步探讨[J]. 中华介入放射学电子杂志, 2023, 11(01): 6-11.
[11] 曾嘉, 何东风. 介入栓塞材料在肝癌治疗中的研究进展[J]. 中华介入放射学电子杂志, 2023, 11(01): 62-67.
[12] 陈丹丹, 潘文志, 陈莎莎, 张源, 张晓春, 李明飞, 周达新, 葛均波. 结构性心脏病年度报告2022[J]. 中华心脏与心律电子杂志, 2023, 11(03): 129-140.
[13] 孙相利, 许真真. 经皮冠状动脉旋磨术在冠状动脉重度钙化病变介入治疗中的应用[J]. 中华老年病研究电子杂志, 2023, 10(02): 33-36.
[14] 姜新鹏, 李晓明, 杨航, 宫一宸, 傅元豪, 傅瑜, 张喆. 单纯经胸超声心动图引导卵圆孔未闭封堵术早期安全性及有效性分析[J]. 中华脑血管病杂志(电子版), 2023, 17(04): 320-324.
[15] 连万成, 姚京, 吴泽涛, 何毅, 伍健明, 张猛. 血流导向装置治疗颅内未破裂动脉瘤的疗效与影响因素分析[J]. 中华脑血管病杂志(电子版), 2023, 17(01): 31-36.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号